Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
http://link.springer.com/article/10.1007/s40265-017-0837-7/fulltext.html
Reference51 articles.
1. Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017: NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(2):230–69.
2. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–57.
3. Usmani S, Ahmadi T, Ng Y, et al. Analysis of real-world data on overall survival in multiple myeloma patients with ≥3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD. Oncologist. 2016;02(21):1355–61.
4. Lonial S, Durie B, Palumbo A, et al. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia. 2016;30(3):526–35.
5. Janssen Biotech Inc. Darzalex (daratumumab) injection, for intravenous use: US prescribing information. 2016. http://www.janssenmd.com . Accessed 25 Oct 2017.
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database;Expert Opinion on Drug Safety;2023-12-18
2. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells;International Journal of Molecular Sciences;2023-12-07
3. TBBPA causes apoptosis in grass carp hepatocytes involving destroyed ER-mitochondrial function;Chemosphere;2023-11
4. Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/ refractory multiple myeloma;The Korean Journal of Internal Medicine;2023-03-01
5. Development of Next-Generation Antibody Therapeutics Using DDS and Molecular Imaging;Handbook of Cancer and Immunology;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3